ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jaybe	5/25/2016 8:42:15 PM
	of 4474

MGH publishes on lack of response to PD-1/L1 inhibitors in EGFRm or ALK+ NSCLC... "In summary, we observed relatively low response rates to PD-1/PD-L1 inhibitors among patients with EGFR-mutant and ALK-positive lung cancer. While this finding requires validation in additional, prospective studies, such initial observations are clinically important. With a range of next-generation EGFR and ALK TKIs currently in the clinic, prioritization of therapies will be particularly important in these molecular subgroups. Despite PD-L1 expression in a subset of EGFR-mutant and ALK-positive NSCLCs, we observed that expression may be dynamic within individual patients, with some exhibiting changes over time and/or in response to treatment. Moreover, only a small subset of EGFR-mutant and ALK-positive NSCLCs demonstrated both PD-L1 expression and high levels of CD8+ TILs. This lack of an inflammatory microenvironment, despite PD-L1 expression, is suggestive of innate immune resistance, and may limit the effectiveness of PD-1/PD-L1 inhibitors in these patient populations." clincancerres.aacrjournals.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next